Overview

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Status:
Active, not recruiting

Trial end date:
2022-03-21

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the efficacy of LNP023 in patients with PNH, showing signs of active hemolysis.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals